恩扎鲁胺
卡巴齐塔塞尔
阿比曲酮
前列腺癌
医学
多西紫杉醇
肿瘤科
内科学
癌症
雄激素剥夺疗法
雄激素受体
作者
Ronald de Wit,Johann S. de Bono,Cora N. Sternberg,Karim Fizazi,Bertrand Tombal,Christian Wülfing,Gero Kramer,Jean‐Christophe Eymard,Aristotelis Bamias,Joan Carles,Roberto Iacovelli,Bohuslav Melichar,Ásgerður Sverrisdóttir,Christine Théodore,Susan Feyerabend,Carole Hélissey,Ayse Ӧzatılgan,Christine Geffriaud-Ricouard,Daniel Castellano
标识
DOI：10.1056/nejmoa1911206
摘要
The efficacy and safety of cabazitaxel, as compared with an androgen-signaling–targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and had progression within 12 months while receiving the alternative inhibitor (abiraterone or enzalutamide) are unclear.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
cdercder
嘻嘻哈哈
无极微光
糊涂的雅琴
潇洒的惋清
OK
学术文献互助
畔畔
GingerF
尊嘟假嘟
挖掘机
pcr163
东方元语
敬老院N号
dl
CFD
张欢馨
殷勤的紫槐
2542
AllRightReserved
皖公网安备34019202002308
